Antibodies as Drugs: Evolving Designs, Formats and Approaches (K7)
February 22-25, 2027
| Fairmont Banff Springs, Banff, AB, Canada
James E Crowe, Jr., Lisa Purcell and Jonah Rainey
Scholarship Deadline: Oct. 30, 2026 | Abstract Deadline: Feb. 3, 2027 | Early Registration Deadline: Dec. 29, 2026
Monday, February 22, 2027
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Tuesday, February 23, 2027
| 8:00–8:10 AM |
Welcome Remarks (Joint) |
|
| 8:10–9:00 AM |
Keynote Address (Joint) |
|
| |
James Zou, Stanford University
The Virtual Lab |
|
| 9:00–11:15 AM |
Drug Design and Preclinical Development: Stimulating Therapeutics and Translation (Joint) |
|
| |
Dean Ho, National University of Singapore
Prospectively Adjusting Human Drug Dosing - Dynamically - for Oncology |
|
| |
Karen Akinsanya †, Schrödinger
Talk Title to be Announced |
|
| |
Philip Kim, University of Toronto
Computation and Artificial Intelligence-Based Methods for Better Antibody Development |
|
| |
Pahini Pandya, Panakeia Technologies
Talk Title to be Announced |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:15–1:00 PM |
Poster Setup |
|
| 11:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Bispecific Antibodies for Co-Engagement and Co-Stimulation |
|
| |
Shelley Force Aldred, Rondo Therapeutics
T-Cell Co-Stimulatory Bispecific Antibodies for Treating Solid Tumors |
|
| |
Ulrike Philippar, Janssen Research & Development
Talk Title to be Announced |
|
| |
Brenda O'Connell †, Bicara Therapeutics
EGFR-TGFb Bifunctional Antibody |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Wednesday, February 24, 2027
| 8:00–11:00 AM |
New Dosing and Use Paradigms for Multispecific Antibodies |
|
| |
Paul W. H. I. Parren, Leiden University Medical Center
Deep-Depletion of Tissue-Resident Pathogenic Immune Cells |
|
| |
Yvonne Y. Chen †, University of California, Los Angeles
Bispecific Logic-Gated CAR-T Cells |
|
| |
Nina Weisser, Zymeworks BC Inc.
TriTCE Co-stim: A Differentiated T Cell Engager Platform with Conditional cis CD28 Co-Stimulation and Transferability to Diverse Targeting Strategies |
|
| |
Jeanette H.W. Leusen, University Medical Center Utrecht
Targeting FcgRI for Auto-Immune Disease |
|
| |
Jonah Rainey, Lilly
Talk Title to be Announced |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–12:00 PM |
Panel Discussion 1: What VCs and Private Investors Really Want: The Difference between Exciting Data and a Value Inflection Point |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:30 PM |
Conditionally and Selectively Active Antibodies |
|
| |
Meike Logtenberg, Merida Biosciences
Selective Binding and Clearance of Pathogenic Antibodies |
|
| |
Sophia Hober, KTH Royal Institute of Technology
Ca Regulated Molecular Switch |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:30–7:00 PM |
Panel Discussion 1: The Cutting-Edge of Antibody Engagement |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Thursday, February 25, 2027
| 8:00–11:00 AM |
Application of Innovations to Exogenous Antibody Targets to Expand Breadth and Efficacy |
|
| |
David Veesler, University of Washington
Antibody Inhibition of Activation Mechanisms of Coronavirus Spike |
|
| |
Laura M Walker, Moderna
Alternative Expression of Antibodies |
|
| |
James E Crowe, Jr., Vanderbilt University Medical Center
Human Monoclonal Antibodies for Emerging Infectious Diseases |
|
| |
Lisa Purcell, Third Rock Ventures
Novel Structure-Guided Functional Improvement of Antibody Breadth and Potency |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–12:00 PM |
Panel Discussion 2: Navigating the Regulatory Landscape: How Companies are Thinking about US Uncertainty and Leveraging Global Regulatory Authorities |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:30 PM |
Novel Scaffolds and Immunoconjugates |
|
| |
Max Houry †, atbtherapeutics
Peptide Payload ATBody |
|
| |
Jason Laliberte, AstraZeneca
VHH-Based Antibodies for Broad Influenza Targeting |
|
| |
Anette Sommer, Synaffix B.V. - Lonza ADS
GlycoConnect® Technology for Best-in-Class ADCs – Emerging Clinical Insights |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:30–7:00 PM |
Panel Discussion 3: How Far Is Too Far: Target Engagement, Computational Design and New Scaffolds |
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
Friday, February 26, 2027
